CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-06 | Biller Jonathan EVP and Chief Legal Officer | Grant or award | +6,294 | 16,863 | ||
| 2024-02-06 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Grant or award | +2,326 | 16,205 | ||
| 2024-02-06 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Grant or award | +3,934 | 20,139 | ||
| 2024-02-06 | Arbuckle Stuart A EVP, COO | Grant or award | +6,976 | 63,532 | ||
| 2024-02-06 | Arbuckle Stuart A EVP, COO | Grant or award | +11,210 | 74,742 | ||
| 2024-02-06 | Ambrose Kristen SVP & Chief Accounting Officer | Grant or award | +2,950 | 9,788 | ||
| 2024-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Grant or award | +5,814 | 37,852 | ||
| 2024-02-06 | ALTSHULER DAVID EVP, Global Research and CSO | Grant or award | +7,866 | 45,718 | ||
| 2024-01-12 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units | +101.04 | $432.99 | $44K | 14,744.26 |
| 2024-01-12 | MCKENZIE DIANA Director | Grant or award · Deferred Stock Units | +76.5 | $432.99 | $33K | 4,822.48 |
| 2024-01-08 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −6,648 | $419.07 | $2.8M | 2,423 |
| 2024-01-02 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Sale 10b5-1 | −3,000 | $405.00 | $1.2M | 43,693 |
| 2023-12-15 | Kewalramani Reshma CEO & President | Exercise or conversion 10b5-1 | +3,058 | $155.57 | $476K | 111,769 |
| 2023-12-15 | Kewalramani Reshma CEO & President | Exercise or conversion 10b5-1 | +14,077 | $187.53 | $2.6M | 125,846 |
| 2023-12-15 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −17,135 | $407.00 | $7.0M | 108,711 |
| 2023-12-15 | Kewalramani Reshma CEO & President | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −3,058 | 0 | ||
| 2023-12-15 | Kewalramani Reshma CEO & President | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −14,077 | 1,565 | ||
| 2023-12-13 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −13,254 | $399.41 | $5.3M | 9,171 |
| 2023-12-13 | LEIDEN JEFFREY M Executive Chairman | Sale 10b5-1 | −100 | $400.19 | $40K | 9,071 |
| 2023-12-13 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −5,098 | $397.00 | $2.0M | 108,711 |
Page 26 of 27 · 524 trades